Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells.

Bauriaud-Mallet M, Vija-Racaru L, Brillouet S, Mallinger A, de Medina P, Rives A, Payre B, Poirot M, Courbon F, Silvente-Poirot S.

J Steroid Biochem Mol Biol. 2019 Sep;192:105390. doi: 10.1016/j.jsbmb.2019.105390. Epub 2019 Jun 3.

PMID:
31170473
2.

Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.

Vija L, Dierickx L, Courbon F.

Ann Endocrinol (Paris). 2019 Jun;80(3):166-171. doi: 10.1016/j.ando.2019.04.005. Epub 2019 Apr 11.

PMID:
31053248
3.

Diagnostic and Therapeutic Uptake of Intrathyroid Metastasis of Midgut Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE Imaging.

Vija Racaru L, Sinigaglia M, Fontaine S, DʼAure D, Courbon F, Dierickx L.

Clin Nucl Med. 2019 Jul;44(7):e445-e448. doi: 10.1097/RLU.0000000000002586.

PMID:
31021912
4.

Gated 18F-FDG PET/CT of the Lung Using a Respiratory Spirometric Gating Device: A Feasibility Study.

Jaudet C, Filleron T, Weyts K, Didierlaurent D, Vallot D, Ouali M, Zerdoud S, Dierickx OL, Caselles O, Courbon F.

J Nucl Med Technol. 2019 Sep;47(3):227-232. doi: 10.2967/jnmt.118.223339. Epub 2019 Apr 24.

PMID:
31019044
5.

Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?

Voglimacci M, Gabiache E, Lusque A, Ferron G, Ducassou A, Querleu D, Motton S, Chantalat E, Courbon F, Martinez A.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1551-1559. doi: 10.1007/s00259-018-4219-5. Epub 2019 Feb 7.

PMID:
30729273
6.

Incidental Finding of Intrathyroid Metastases of Prostatic Cancer on 18F-Choline PET/CT.

Vija Racaru L, Gabiache E, Fontaine S, DʼAure D, Mourey L, Courbon F, Zerdoud S.

Clin Nucl Med. 2019 Feb;44(2):e101-e103. doi: 10.1097/RLU.0000000000002374.

PMID:
30516690
7.

Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.

Vija Racaru L, Sinigaglia M, Kanoun S, Ben Bouallègue F, Tal I, Brillouet S, Bauriaud-Mallet M, Zerdoud S, Dierickx L, Vallot D, Caselles O, Gabiache E, Pascal P, Courbon F.

Nucl Med Commun. 2018 Jul;39(7):672-679. doi: 10.1097/MNM.0000000000000850.

8.

Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E.

Clin Pharmacokinet. 2019 Feb;58(2):213-222. doi: 10.1007/s40262-018-0674-1.

PMID:
29736841
9.

Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.

Pascal P, Dercle L, Weyts K, Meyer N, Courbon F.

Clin Nucl Med. 2018 May;43(5):333-334. doi: 10.1097/RLU.0000000000002032.

PMID:
29485438
10.

18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.

Gillebert Q, Huchet V, Rousseau C, Cochet A, Olivier P, Courbon F, Gontier E, Nataf V, Balogova S, Talbot JN; other ICHOROPRO investigators.

PLoS One. 2018 Feb 9;13(2):e0191487. doi: 10.1371/journal.pone.0191487. eCollection 2018.

11.

Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know.

Kanoun S, Cottereau AS, Berriolo-Riedinger A, Meignan M, Casasnovas O, Courbon F, Kraeber-Bodéré F.

J Nucl Med. 2018 Apr;59(4):714-715. doi: 10.2967/jnumed.117.205351. Epub 2017 Dec 21. No abstract available.

12.

A clinical evaluation of the impact of the Bayesian penalized likelihood reconstruction algorithm on PET FDG metrics.

Vallot D, Caselles O, Chaltiel L, Fernandez A, Gabiache E, Dierickx L, Zerdoud S, Bauriaud M, Courbon F.

Nucl Med Commun. 2017 Nov;38(11):979-984. doi: 10.1097/MNM.0000000000000729.

PMID:
29045338
13.

Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response.

Vija Racaru L, Fontan C, Bauriaud-Mallet M, Brillouet S, Caselles O, Zerdoud S, Bastié D, Vallot D, Caron P, Bardiès M, Courbon F.

Nucl Med Commun. 2017 Sep;38(9):756-763. doi: 10.1097/MNM.0000000000000705.

PMID:
28719405
14.
15.

Evaluation of 2 diuretic 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography imaging protocols for intrapelvic cancer.

Dierickx LO, Dercle L, Chaltiel L, Caselles O, Brillouet S, Zerdoud S, Courbon F.

Q J Nucl Med Mol Imaging. 2019 Sep;63(3):284-291. doi: 10.23736/S1824-4785.17.02912-0. Epub 2017 Mar 29.

PMID:
28358186
16.

Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study).

Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, Hapdey S, Pallardy A, Mahé MA, Lacombe M, Boisselier P, Guillemard S, Olivier P, Beckendorf V, Salem N, Charrier N, Chajon E, Devillers A, Aide N, Danhier S, Denis F, Muratet JP, Martin E, Riedinger AB, Kolesnikov-Gauthier H, Dansin E, Massabeau C, Courbon F, Farcy Jacquet MP, Kotzki PO, Houzard C, Mornex F, Vervueren L, Paumier A, Fernandez P, Salaun M, Dubray B.

J Nucl Med. 2017 Jul;58(7):1045-1053. doi: 10.2967/jnumed.116.188367. Epub 2017 Mar 2.

17.

Oncocytic Adenoma of Thyroid Incidentally Detected by 18F-Fluorocholine PET/CT.

Aziz AL, Courbon F, Dierickx LO, Pascal P, Zerdoud S.

J Nucl Med Technol. 2015 Jun;43(2):133-4. doi: 10.2967/jnmt.114.145433. Epub 2015 Apr 9.

18.
19.

Comparison of an alternative and existing binning methods to reduce the acquisition duration of 4D PET/CT.

Didierlaurent D, Jaudet C, Ribes S, Batatia H, Dierickx LO, Zerdoud S, Brillouet S, Weyts K, Courbon F, Caselles O.

Med Phys. 2014 Nov;41(11):112503. doi: 10.1118/1.4897612.

PMID:
25370662
20.

Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?

Dercle L, Chisin R, Ammari S, Gillebert Q, Ouali M, Jaudet C, Delord JP, Dierickx L, Zerdoud S, Schlumberger M, Courbon F.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):397-408. doi: 10.1007/s00259-014-2938-9. Epub 2014 Nov 1.

PMID:
25367748
21.

Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art.

de Mestier L, Dromain C, d'Assignies G, Scoazec JY, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d'Herbomez M, Cadiot G.

Endocr Relat Cancer. 2014 Apr 28;21(3):R105-20. doi: 10.1530/ERC-13-0365. Print 2014 Jun. Review.

PMID:
24351682
22.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H.

Eur J Cancer. 2014 Jan;50(1):170-7. doi: 10.1016/j.ejca.2013.08.012. Epub 2013 Sep 7.

PMID:
24021349
23.

Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.

Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, Cachin F, Berriolo-Riedinger A, Olivier P, Kolesnikov-Gauthier H, Blagosklonov O, Bridji B, Devillers A, Collombier L, Courbon F, Gremillet E, Houzard C, Caignon JM, Roux J, Aide N, Brenot-Rossi I, Doyeux K, Dubray B, Vera P.

J Nucl Med. 2013 Sep;54(9):1543-50. doi: 10.2967/jnumed.112.118083. Epub 2013 Aug 5.

24.

A new respiratory gating device to improve 4D PET/CT.

Didierlaurent D, Ribes S, Caselles O, Jaudet C, Cazalet JM, Batatia H, Courbon F.

Med Phys. 2013 Mar;40(3):032501. doi: 10.1118/1.4789487.

PMID:
23464338
25.

Breast imaging: understanding how accuracy is measured when lesion are the unit of analysis.

Filleron T, Dalenc F, Courbon F, Feillel V, Kramar A.

Breast J. 2013 Mar-Apr;19(2):225-6. doi: 10.1111/tbj.12093. No abstract available.

PMID:
23458221
26.

The retrospective binning method improves the consistency of phase binning in respiratory-gated PET/CT.

Didierlaurent D, Ribes S, Batatia H, Jaudet C, Dierickx LO, Zerdoud S, Brillouet S, Caselles O, Courbon F.

Phys Med Biol. 2012 Dec 7;57(23):7829-41. doi: 10.1088/0031-9155/57/23/7829. Epub 2012 Nov 8.

PMID:
23135238
27.

Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases.

Wagner T, Chevreau C, Meyer N, Mourey L, Courbon F, Zerdoud S.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1431-5. doi: 10.1111/j.1468-3083.2011.04312.x. Epub 2011 Oct 24.

PMID:
22017492
28.

Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose.

Dierickx LO, Huyghe E, Nogueira D, Zerdoud S, Filleron T, Brillouet S, Delauney B, Montagut J, Bujan L, Plante P, Courbon F.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):129-37. doi: 10.1007/s00259-011-1929-3. Epub 2011 Sep 10.

PMID:
21909754
29.

Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands.

de Medina P, Paillasse MR, Ségala G, Khallouki F, Brillouet S, Dalenc F, Courbon F, Record M, Poirot M, Silvente-Poirot S.

Chem Phys Lipids. 2011 Sep;164(6):432-7. doi: 10.1016/j.chemphyslip.2011.05.005. Epub 2011 May 27. Review.

PMID:
21641337
30.

Evaluation of a trainer phantom in the learning phase of sentinel lymph node identification in breast cancer.

Lèguevaque P, Motton S, Courbon F, Ricard M, Berry I, Querleu D.

World J Surg. 2011 May;35(5):995-1001. doi: 10.1007/s00268-011-0997-7.

PMID:
21365341
31.

Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.

Wagner T, Meyer N, Zerdoud S, Julian A, Chevreau C, Payoux P, Courbon F.

Br J Dermatol. 2011 Jun;164(6):1235-40. doi: 10.1111/j.1365-2133.2011.10247.x. Epub 2011 May 13.

PMID:
21332457
32.

Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.

Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, Brillouet S, Canal P, Courbon F, Allal BC.

Clin Cancer Res. 2010 Sep 1;16(17):4434-45. doi: 10.1158/1078-0432.CCR-09-2795. Epub 2010 Jul 26.

33.

Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition.

Metwally H, Courbon F, David I, Filleron T, Blouet A, Rives M, Izar F, Zerdoud S, Plat G, Vial J, Robert A, Laprie A.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):793-9. doi: 10.1016/j.ijrobp.2010.02.024. Epub 2010 Jul 7.

PMID:
20615626
34.

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Delord JP, Quideau S, Rochaix P, Caselles O, Couderc B, Hennebelle I, Courbon F, Canal P, Allal BC.

Br J Cancer. 2010 Jun 29;103(1):61-72. doi: 10.1038/sj.bjc.6605699. Epub 2010 Jun 1.

35.

Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.

Brillouet S, Dorbes S, Courbon F, Picard C, Delord JP, Benoist E, Poirot M, Mestre-Voegtlé B, Silvente-Poirot S.

Bioorg Med Chem. 2010 Jul 15;18(14):5400-12. doi: 10.1016/j.bmc.2010.05.031. Epub 2010 May 19.

PMID:
20542702
36.

Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.

Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L.

J Clin Oncol. 2008 Feb 20;26(6):963-70. doi: 10.1200/JCO.2007.12.7431.

PMID:
18281671
37.

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.

Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, Allal BC, Courbon F, Chatelut E, Delord JP.

Clin Cancer Res. 2007 Dec 1;13(23):7086-92.

38.

Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism.

Vezzosi D, Bennet A, Courbon F, Caron P.

Clin Endocrinol (Oxf). 2008 Jun;68(6):904-11. Epub 2007 Nov 19.

PMID:
18031316
39.

Adenoid cystic carcinoma of the lung: interest of 18FDG PET/CT in the management of an atypical presentation.

Campistron M, Rouquette I, Courbon F, Chabbert V, Rochaix P, Prévot G, Laroumagne S, Têtu L, Didier A, Mazières J.

Lung Cancer. 2008 Jan;59(1):133-6. Epub 2007 Jul 20.

PMID:
17640764
40.

[Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].

Bourguet P, Planchamp F, Montravers F, Vincendeau S, Courbon F, Edeline V, Helal BO, Rossi D, Villers A; Standards, Options et Recommandations (SOR); Institut National du Cancer; Fédération nationale des centres de lutte contre le cancer (FNCLCC); Ligue Nationale contre le Cancer; SFMN; Fédération hospitalière de France (FHF); Fédération nationale de cancérologie des CHRU (FNCHRU); Fédération française de cancérologie des CHG (FFCCHG).

Bull Cancer. 2006 Dec;93(12):1228-32. French. No abstract available.

41.

Preparation and use of 131I magic gel as a dosimeter for targeted radionuclide therapy.

Courbon F, Love P, Chittenden S, Flux G, Ravel P, Cook G.

Cancer Biother Radiopharm. 2006 Oct;21(5):427-36.

PMID:
17105417
42.

Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.

Courbon F, Caselles O, Zerdoud S, Duthil P, Regis H, Berry I, Caron P.

Q J Nucl Med Mol Imaging. 2006 Dec;50(4):363-70.

43.

Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma.

Courbon F, Zerdoud S, Bastie D, Archambaud F, Hoff M, Eche N, Berry I, Caron P.

Thyroid. 2006 Oct;16(10):1025-31.

PMID:
17042689
44.

V-Q SPECT in prone position is a suitable way to improve irradiation of inoperable lung cancer.

Courbon F, Caselles O, François P, Boneu A, McNamara D, Bachaud JM.

Clin Nucl Med. 2006 May;31(5):284-8. No abstract available.

PMID:
16622339
45.

[The impact of 18F-fluorodeoxyglucose positron emission tomography on the 3D conformal radiotherapy planning in patients with non-small cell lung cancer].

Bachaud JM, Marre D, Dygai I, Caselles O, Hamelin D, Bègue M, Laprie A, Zerdoud S, Gancel M, Courbon F.

Cancer Radiother. 2005 Dec;9(8):602-9. Epub 2005 Nov 28. Review. French.

PMID:
16316759
46.

The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer.

Christian JA, Partridge M, Nioutsikou E, Cook G, McNair HA, Cronin B, Courbon F, Bedford JL, Brada M.

Radiother Oncol. 2005 Dec;77(3):271-7. Epub 2005 Nov 7.

PMID:
16274762
47.

Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.

Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P.

Eur J Endocrinol. 2005 May;152(5):757-67.

PMID:
15879362
48.

Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002).

Bourguet P, Blanc-Vincent MP, Boneu A, Bosquet L, Chauffert B, Corone C, Courbon F, Devillers A, Foehrenbach H, Lumbroso JD, Mazselin P, Montravers F, Moretti JL, Talbot JN; FNCLCC PET-Scanning Committee.

Br J Cancer. 2003 Aug;89 Suppl 1:S84-91. No abstract available.

49.

Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease.

Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, Rascol O, Senard JM.

Mov Disord. 2003 Aug;18(8):890-7.

PMID:
12889078
50.

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.

Ravaud A, Delaunay M, Chevreau C, Coulon V, Debled M, Bret-Dibat C, Courbon F, Gualde N, Nguyen Bui B.

Br J Cancer. 2001 Nov 16;85(10):1467-71.

Supplemental Content

Loading ...
Support Center